Department of Pharmacy, Shizuoka General Hospital, Shizuoka City, Japan.
Cancer Rep (Hoboken). 2021 Aug;4(4):e1371. doi: 10.1002/cnr2.1371. Epub 2021 Mar 19.
The differences in the clinical pharmacy services (CPS) provided by oncology and non-oncology pharmacists have not been sufficiently explained.
This study aimed to demonstrate the differences in direct CPS provided by oncology and non-oncology pharmacists for patients and physicians, and to assess the potential impact of these services on medical costs.
We retrospectively examined CPS provided by oncology and non-oncology pharmacists for outpatients who underwent chemotherapy between January and December 2016.
In total, 1177 and 1050 CPS provided by oncology and non-oncology pharmacists, respectively, were investigated. The rates of interventions performed by oncology and non-oncology pharmacists for physicians-determined treatment were 18.5% and 11.3%, respectively (p < .001). The rates of oncology and non-oncology pharmacist interventions accepted by physicians were 84.6 and 78.8%, respectively (p = .12). Level 4 and Level 5 interventions accounted for 64.6% of all oncology pharmacist interventions and 53.0% of all non-oncology pharmacist interventions (p = .03). The rates of improvement in symptoms from adverse drug reactions among patients resulting from interventions by oncology and non-oncology pharmacists were 89.4 and 72.1%, respectively (p = .02). Conservative assessments of medical cost impact showed that a single intervention by an oncology and by a non-oncology pharmacist saved ¥6355 and ¥3604, respectively.
The results of the present study suggested that CPS by oncology pharmacists enable safer and more effective therapy for patients with cancer and indirectly contribute to reducing health care fees.
肿瘤和非肿瘤药师提供的临床药学服务（CPS）的差异尚未得到充分解释。
本研究旨在展示肿瘤和非肿瘤药师为患者和医师提供的直接 CPS 的差异，并评估这些服务对医疗费用的潜在影响。
我们回顾性地检查了 2016 年 1 月至 12 月期间接受化疗的门诊患者的肿瘤和非肿瘤药师提供的 CPS。
共调查了肿瘤和非肿瘤药师分别为 1177 例和 1050 例患者提供的 CPS。肿瘤和非肿瘤药师对医师确定的治疗进行干预的比例分别为 18.5%和 11.3%（p < .001）。医师接受肿瘤和非肿瘤药师干预的比例分别为 84.6%和 78.8%（p = .12）。4 级和 5 级干预占所有肿瘤药师干预的 64.6%和所有非肿瘤药师干预的 53.0%（p = .03）。肿瘤和非肿瘤药师干预导致不良反应症状改善的比例分别为 89.4%和 72.1%（p = .02）。对医疗费用影响的保守评估表明，肿瘤和非肿瘤药师的单次干预分别节省了 ¥6355 和 ¥3604。
本研究结果表明，肿瘤药师的 CPS 使癌症患者的治疗更加安全有效，并间接有助于降低医疗费用。
